← Back

Wire · opportunities

FDA Okays Once-Weekly Tx for Turner Syndrome Growth Failure

Published

21 November 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at medscape.com →

◆ Verified

Fusion42 · 21 November 2026 · Fusion42 review

The FDA has approved the once-weekly long-acting growth hormone somapacitan-beco (Sogroya, Novo Nordisk) for treating growth failure in children aged 2.5 years and older with Turner syndrome. This new indication expands somapacitan-beco’s use beyond previous approvals for growth hormone deficiency and other pediatric growth conditions.

This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it between 20 Nov 2026 and 21 Nov 2026.

◆ ◆ The Wire takeaway

You can now offer a once-weekly injection to young patients with Turner syndrome, removing daily dosing barriers and opening your clinic to more compliant treatments. This marks a rare chance to differentiate in pediatric endocrinology with better patient adherence.

◆ Coverage

2 sources · first reported 20 Nov 2026 · latest 21 Nov 2026

◆ Related on Wire

◆ Topics

Biotechfda-approvalturner-syndromegrowth-hormonepediatric-treatmentnovo-nordisk